ZA200703154B - Methods of treating CD30 positive lymphomas - Google Patents

Methods of treating CD30 positive lymphomas

Info

Publication number
ZA200703154B
ZA200703154B ZA200703154A ZA200703154A ZA200703154B ZA 200703154 B ZA200703154 B ZA 200703154B ZA 200703154 A ZA200703154 A ZA 200703154A ZA 200703154 A ZA200703154 A ZA 200703154A ZA 200703154 B ZA200703154 B ZA 200703154B
Authority
ZA
South Africa
Prior art keywords
treating
methods
positive lymphomas
lymphomas
positive
Prior art date
Application number
ZA200703154A
Other languages
English (en)
Inventor
Von Strandmann Elke Pogge
Engert Andreas
Borchmann Peter
Boeell Boris
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of ZA200703154B publication Critical patent/ZA200703154B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200703154A 2004-10-01 2005-09-30 Methods of treating CD30 positive lymphomas ZA200703154B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61528404P 2004-10-01 2004-10-01

Publications (1)

Publication Number Publication Date
ZA200703154B true ZA200703154B (en) 2008-09-25

Family

ID=35929979

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200703154A ZA200703154B (en) 2004-10-01 2005-09-30 Methods of treating CD30 positive lymphomas

Country Status (13)

Country Link
US (1) US7790160B2 (enExample)
EP (1) EP1802345A2 (enExample)
JP (1) JP2008514730A (enExample)
KR (1) KR20070083899A (enExample)
CN (1) CN101056655A (enExample)
AU (1) AU2005292227A1 (enExample)
BR (1) BRPI0516727A (enExample)
CA (1) CA2582016A1 (enExample)
IL (1) IL182260A0 (enExample)
MX (1) MX2007003533A (enExample)
NO (1) NO20071714L (enExample)
WO (1) WO2006039644A2 (enExample)
ZA (1) ZA200703154B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471938A4 (en) * 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
US20090175886A1 (en) * 2006-01-17 2009-07-09 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
EP2155231B1 (en) * 2007-04-10 2012-08-08 The Johns Hopkins University Imaging and therapy of virus-associated tumors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
AU2013216863B2 (en) 2012-02-10 2018-09-06 Seagen Inc. Detection and treatment of CD30+ cancers
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
RS64268B1 (sr) 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
WO2015061752A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US10335494B2 (en) * 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
CA2954694A1 (en) * 2014-07-11 2016-01-14 Expression Pathology, Inc. Srm/mrm assay for the tumor necrosis factor receptor superfamily member 8 (cd30) protein
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
MA45862A (fr) * 2016-08-04 2021-05-05 Millennium Pharm Inc Combinaison d'inhibiteurs du protéasome et d'anticorps anti-cd30
CN106854245A (zh) * 2016-12-28 2017-06-16 无锡傲锐东源生物科技有限公司 抗cd30蛋白单克隆抗体及其用途
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
WO2018222718A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
WO2019148410A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1 antibodies
MX2021005048A (es) 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
CA3196496A1 (en) 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
CN116964098A (zh) 2021-03-01 2023-10-27 南特生物公司 抗cd30单克隆抗体和嵌合抗原受体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
WO1991007437A2 (en) 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE4200043A1 (de) 1991-11-11 1993-05-13 Stein Harald Prof Dr Lymphoides cd30-antigen (ki-1), dessen protein- und die zugehoerige nucleotidsequenz, seine herstellung sowie mittel zur diagnose und untersuchung von tumoren
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
AU4953693A (en) 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
ATE186745T1 (de) 1995-01-18 1999-12-15 Roche Diagnostics Gmbh Antikörper gegen cd30, die proteolytische spaltung und abgabe des membrangebundenen cd30 antigens verhindern
DE19543039C1 (de) 1995-11-08 1996-11-21 Medac Klinische Spezialpraep Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP1053316A1 (de) 1998-02-06 2000-11-22 AbGen GmbH Nukleinsäuren zur modulation zellulärer aktivierung
DE19937264A1 (de) 1999-08-06 2001-02-15 Deutsches Krebsforsch F¶v¶-Antikörper-Konstrukte
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
WO2002017979A2 (en) 2000-08-29 2002-03-07 Noveon Ip Holdings Corp. Dehydrated hydrogels
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
PL213948B1 (pl) * 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
EP1471938A4 (en) * 2002-01-09 2008-03-05 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST CD30
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
MX2007003533A (es) 2004-10-01 2007-05-23 Medarex Inc Metodos de tratar linfomas cd30 positivas.
US8207303B2 (en) 2005-02-18 2012-06-26 Medarex, Inc. Monoclonal antibodies against CD30 lacking in fucosyl residues

Also Published As

Publication number Publication date
MX2007003533A (es) 2007-05-23
WO2006039644A2 (en) 2006-04-13
WO2006039644A3 (en) 2006-08-10
US7790160B2 (en) 2010-09-07
BRPI0516727A (pt) 2008-09-16
NO20071714L (no) 2007-06-28
CA2582016A1 (en) 2006-04-13
KR20070083899A (ko) 2007-08-24
AU2005292227A1 (en) 2006-04-13
IL182260A0 (en) 2007-07-24
CN101056655A (zh) 2007-10-17
US20060177442A1 (en) 2006-08-10
EP1802345A2 (en) 2007-07-04
JP2008514730A (ja) 2008-05-08

Similar Documents

Publication Publication Date Title
IL182260A0 (en) Methods of treating cd30 positive lymphomas
ZA201207323B (en) Method of treatment of prophylaxis
PL2302097T3 (pl) Metoda obróbki powierzchni
IL207688A0 (en) Methods of treating skin disorders using an il-31ra antagonist
EP1737550A4 (en) INORGANIC SALT RECOVERY DURING THE TREATMENT OF LIGNOCELLULOSIC FOODS
EP1948301A4 (en) TREATMENT OF BRONCHIC CONSTRICTION BY ELECTRICAL STIMULATION
IL182011A0 (en) Treatment screening methods
IL183889A0 (en) Treatment method
IL193460A0 (en) Compounds and methods for treatment of stroke
EP2032131A4 (en) Methods of Treatment
IL182436A0 (en) Thienopyridinone compounds and methods of treatment
EP1959931A4 (en) COMPOSITIONS AND METHODS FOR THE DERMAL TREATMENT OF PAIN
EP1809265A4 (en) Methods for the treatment of synucleinopathies
IL178996A0 (en) Thienopyridinone compounds and methods of treatment
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
GB0610746D0 (en) Method of treatment
ZA200607115B (en) Permanent treatment method
GB0402578D0 (en) Methods of treatment of atherosclerosis
GB0426196D0 (en) Methods of treatment
GB2430002B (en) Well treatment
ZA200709024B (en) Method of well treatment and construction
EP1809276A4 (en) PROCESSING PROCESS
GB0424085D0 (en) Well treatment
HK1099997A (en) Methods of treating cd30 positive lymphomas
GB2412585B (en) Muscle treatment